Informationen:
Fehler:
ID
22970
Beschreibung
Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT00425321
Link
https://clinicaltrials.gov/show/NCT00425321
Stichworte
Versionen (1)
- 19.06.17 19.06.17 -
Hochgeladen am
19. Juni 2017
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Rheumatoid Arthritis NCT00425321
Eligibility Rheumatoid Arthritis NCT00425321
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Rheumatoid Arthritis NCT00425321
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Rheumatoid Arthritis disease length | Tender joint count | Swollen joint count
Item
patients diagnosed with rheumatoid arthritis for at least 6 months with at least 8 tender and 8 swollen joints
boolean
C0003873 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
C0451530 (UMLS CUI [2])
C0451521 (UMLS CUI [3])
C0872146 (UMLS CUI [1,2])
C0451530 (UMLS CUI [2])
C0451521 (UMLS CUI [3])
Methotrexate
Item
methotrexate treatment for 6 months
boolean
C0025677 (UMLS CUI [1])
Dose Stable U/week
Item
at least 10mg/wk and stable dose for at least 8 weeks
boolean
C0178602 (UMLS CUI [1,1])
C0205360 (UMLS CUI [1,2])
C0560588 (UMLS CUI [1,3])
C0205360 (UMLS CUI [1,2])
C0560588 (UMLS CUI [1,3])
Tuberculosis test negative
Item
negative tb screening
boolean
C2242735 (UMLS CUI [1])
Antirheumatic Drugs, Disease-Modifying | Methotrexate
Item
use of other disease-modifying anti-rheumatic drugs (dmards) (other than methotrexate mtx)
boolean
C0242708 (UMLS CUI [1])
C0025677 (UMLS CUI [2])
C0025677 (UMLS CUI [2])
Anti-tumor necrosis factor alpha drug Quantity
Item
previous use of more than 1 anti-tnf (tumor necrosis factor) agent
boolean
C1562242 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,2])
Cytotoxic agent | MAP kinase p38 inhibitor | Anti-CD4 Monoclonal Antibody
Item
previous use of cytotoxics, p38 mapkinase inhibitor, anti-cd4 antibody
boolean
C0304497 (UMLS CUI [1])
C1120843 (UMLS CUI [2,1])
C0243077 (UMLS CUI [2,2])
C3831519 (UMLS CUI [3])
C1120843 (UMLS CUI [2,1])
C0243077 (UMLS CUI [2,2])
C3831519 (UMLS CUI [3])
Vaccines, Attenuated
Item
receipt of live vaccine within 1 month of study drug
boolean
C0042211 (UMLS CUI [1])
Communicable Disease Serious | Chronic infectious disease | Recurrent infections | Opportunistic Infection
Item
serious infection in previous 2 months or history of chronic or recurrent infectious disease or history of opportunistic infection
boolean
C0009450 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0151317 (UMLS CUI [2])
C0239998 (UMLS CUI [3])
C0029118 (UMLS CUI [4])
C0205404 (UMLS CUI [1,2])
C0151317 (UMLS CUI [2])
C0239998 (UMLS CUI [3])
C0029118 (UMLS CUI [4])
Disease Clinical Significance Organ system
Item
other clinically significant disease of other organ system
boolean
C0012634 (UMLS CUI [1,1])
C2826293 (UMLS CUI [1,2])
C0460002 (UMLS CUI [1,3])
C2826293 (UMLS CUI [1,2])
C0460002 (UMLS CUI [1,3])